ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer Ingelheim Acquires Liver Drug

by Rick Mullin
May 25, 2015 | APPEARED IN VOLUME 93, ISSUE 21

Boehringer Ingelheim has acquired an investigational drug to treat nonalcoholic steatohepatitis, a liver disease, from Australia’s Pharmaxis. The drug, PXS4728A, is a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 inhibitor that works by blocking leukocyte adhesion and tissue infiltration in inflammatory processes. Boehringer Ingelheim will pay about $30 million up front, and Pharm­axis will be eligible to receive development and commercialization milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment